Introduction
Altered expression of nuclear retinoid receptors is associated with malignant transformation of human cells (reviewed in . For example, RAR-b expression is suppressed progressively during tumor development in the oral cavity (Hu et al., 1991; Lotan et al., 1995) and in cancers of the lung (Gebert et al., 1991; Xu et al., 1997b) , breast (Swisshelm et al., 1994; Xu et al., 1997a) , and esophagus (Qiu et al., 1999) . Many lung and esophageal cancer cell lines that do not express RAR-b are resistant to growth inhibition by retinoids (Geradts et al., 1993; . Speci®cally, RAR-b mRNA, which is present in normal esophageal epithelial cells, is frequently diminished in premalignant and malignant esophageal epithelia (Qiu et al., 1999) . The sensitivity of esophageal cancer cells to RA is associated with the expression and upregulation of RAR-b . These data indicate that the progressive suppression of RAR-b expression may be an essential step in the malignant transformation of epithelial cells and may be associated with RA resistance in cancer cells (reviewed in . Therefore, characterizing RAR-b-regulated genes may help us better understand how retinoids regulate cell growth and dierentiation and suppress carcinogenesis.
RA can suppress tumor promoter-mediated induction of cyclooxygenase (COX)-2 expression in both normal and malignant cells (Goldstein et al., 1984; Mestre et al., 1997a,b) . COX-2 is a key enzyme in the metabolism of arachidonate to prostaglandin E 2 (PGE 2 ) (Taketo, 1998a,b) . COX-2 expression is frequently elevated in a number of cancers, including esophageal cancer (Taketo, 1998a,b; Zimmermann et al., 1999) , and is induced by various agents such as growth factors and tumor promoters (Mestre et al., 1997a,b) . Overexpression of the COX-2 gene showed altered adhesion properties and apoptosis, whereas knockout of COX-2 reduced the number and size of the intestinal polyps dramatically (Oshima et al., 1996) . These observations suggested that overexpression of COX-2 may be involved in carcinogenesis or metastasis (Oshima et al., 1996; Tsujii and DuBois, 1995; Tsujii et al., 1997) . However, many chemopreventive agents, e.g., nonsteroidal anti-in¯am-matory drugs (NSAIDs) (Tsujii and DuBois, 1995) can inhibit COX-2 enzymatic activity and its associated phenotypes (Taketo, 1998a,b) . Several reports have indicated an association between use of NSAIDs and decreased risk of developing esophageal cancer (Farrow et al., 1998; Funkhouser and Sharp, 1995) . NSAIDs inhibit endogenous prostaglandin synthesis, which plays a role in controlling neoplastic and non-neoplastic cell proliferation and immune function (Taketo, 1998a,b) . Our recent study demonstrated that induction of apoptosis by a NSAID NS398 in esophageal cancer cells was associated with COX-2 expression and was through the cytochrome c-dependent pathway (Li et al., 2001) . Therefore, it may be possible to inhibit cancer cell growth or even prevent carcinogenesis by inhibiting COX-2 enzyme activity (Sheng et al., 1997; Tsujii and DuBois, 1995) .
In this study, we stably transfected an RAR-b expression vector into an esophageal cancer cell line TE-8, in which RAR-b is neither expressed nor induced by RA. In addition, we stably expressed antisense RAR-b in TE-3 cells, which express RAR-b and are sensitive to RA. Our data showed that induction of RAR-b decreased tumor cell growth and colony formation and induced apoptosis in TE-8 cells. In contrast, antisense RAR-b-transfected TE-3 cells had a shorter doubling time and became resistant to RA. Induction of RAR-b expression inhibited COX-2 expression, while the blockage of RAR-b expression increased COX-2 expression. The RAR antagonist AGN193109 blocked the reduction of COX-2 expression by RA in the TE-8 transfectants, whereas the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) had no eect. Meanwhile, RA blocked bile acidinduced COX-2 expression and prostaglandin E 2 production only in the RAR-b positive cells. The anticancer eect of RAR-b may be related to its ability to suppress COX-2 expression and supports that the loss of RAR-b expression may contribute to esophageal carcinogenesis.
Results

Characterization of esophageal cancer cells stably transfected with sense and antisense RAR-b
To study the role of RAR-b or its regulated genes in esophageal cancer, we stably transfected an RAR-b expression vector into RAR-b-negative esophageal cancer cell line TE-8 and an RAR-b antisense vector into RAR-b-positive TE-3 cells. The TE-8 transfectants expressed both RAR-b mRNA and protein, whereas TE-3 subclones expressed endogenous and exogenous RAR-b mRNA and but expressed much less RAR-b protein (Figure 1a,b) . The expression of RAR-a and RAR-g in these transfectants was not changed, even after RA treatment (data not shown).
The cell doubling times of various stable clones are shown in Table 1 . TE-8 transfectants grew about 40% slower, whereas the TE-3 transfectants grew about 40% faster as compared to the vector-only transfectants. Meanwhile, the TE-8 transfectants became sensitive to RA treatment and underwent apoptosis. The addition of prostaglandin E 2 (PGE 2 ) into the culture media antagonized the RA's eect on reduction of the cell viability. Furthermore, the TE-3 transfec- tants were resistant to RA (Figure 1c ). In addition, cells from the TE-8 transfectants enlarged and attened, suggesting that they had undergone squamous dierentiation (data not shown). In colony formation assay, TE-8 transfectants lost the ability to grow in soft agar (data not shown).
Expression and modulation of COX-2 and PGE 2 by RA in
RAR-b transfectants
Previous studies have demonstrated that RA can suppress COX-2 expression that induced by dierent tumor promoters such as bile acid or EGF. Thus, we analysed COX-2 expression in these transfectants. Figure 2a shows that the level of COX-2 protein is lower in RAR-b-transfected TE-8S20 and TE-8S22 cells than in vector-only transfected TE-8V1 cells. In contrast, COX-2 expression is higher in TE-3A3 and TE-3A5 cells than in TE-3V1 cells. Levels of COX-1 protein in these cells were similar, showing no changes, even after RA treatment (data not shown). We then treated these cells with 1 mM RA for up to 24 h and the treatment further reduced the level of COX-2 protein in TE-8 transfectants in a time-dependent manner. In contrast, RA-induced inhibition of COX-2 expression was abolished in TE-3A3 and TE-3A5 cells ( Figure  2b ). Next, we analysed the level of the COX-2 product PGE 2 by ELISA and showed that the PGE 2 levels were low in TE-8S20 and TE-8S22 cells and RA treatment further reduced PGE 2 production in these cells ( Figure   3c ). These data suggest that inhibition of COX-2 depends on RAR-b expression in esophageal cancer cells.
Effect of RAR-b on induction of COX-2 expression by bile acid
Previous studies demonstrated that bile acids, potential tumor promoters in gastrointestinal carcinogenesis, can markedly induce both COX-2 mRNA and protein levels in esophageal cancer cell lines (Zhang et al., 1998) and RA can inhibit COX-2 expression (Mestre et al., 1997a,b) but the mechanism is unknown. Therefore, we like to determine whether bile acid-induction of COX-2 and its inhibition by RA are RAR-b dependent, and further investigate the eect of RARb on COX-2 expression. After adding a bile acid chenodeoxycholate (CD) into culture media of TE-8 and its transfectants, both COX-2 protein ( Figure 3a ) and mRNA ( Figure 3b , and ELISA (c). The cells were seeded for 24 h and treated with 1 mM of RA for 8 h and then treated with 400 mM CD for 12 h, and mRNA, cellular protein were then extracted and subjected to Northern or Western blot analyses, respectively, three times of 400 ml of conditioned media were used for ELISA. All the experiments were repeated twice
by CD only in RAR-b transfectants, but not in vectoronly transfectants (Figure 3) . Consistent with the observation that COX-2 is mainly responsible for PGE 2 synthesis, CD treatment increased PGE 2 production in both RAR-b and vector-only transfectants. However, RA inhibited PGE 2 production only in RAR-b transfectants, but not in vector-only transfectants (Figure 3c ). The results clearly demonstrated that inhibition of CD-mediated COX-2 expression by RA is dependent on RAR-b expression. As for COX-1, our previous study showed that CD was unable to alter its expression in seven esophageal cancer cell lines, including TE-3 and TE-8 (Li et al., 2000) .
Transcriptional regulation of COX-2 expression
Nuclear run-o assays were used to determine whether the changes in COX-2 mRNA levels modulated by CD and/or RA were due to new transcription or mRNA stabilization. As shown in Figure 4a , COX-2 mRNA synthesis increased after CD treatment and decreased after addition of RA, consistent with the Northern blotting data (Figure 3a) . Meanwhile, we investigated eects of CD, RA, and RAR-b expression on COX-2 promoter activity by transient transfection with a human COX-2 promoter-luciferase construct. Induction of COX-2 promoter activity by CD treatment was inhibited by RA in sense RAR-b transfectants, but not in vector-only transfectants or parental cells ( Figure  4b ). Cotransfection of RAR-b inhibited COX-2 promoter activity in parental TE-8 cells (Figure 4c ), indicating that the results from TE-8S20 cells ( Figure  4b) were not due to clonal selection during stable transfection.
RAR-specific effect of RA on COX-2 expression
To determine whether RA inhibition of COX-2 induction by CD is RAR-dependent, we used the RAR-a/-b/-g antagonist AGN193109 to block the eect of RA on COX-2 expression. Figure 5a shows that AGN193109 signi®cantly inhibited the eect of RA on COX-2 protein expression in one of the RAR-b transfected lines TE-8S20. We also used the synthetic retinoid 4-HPR, which acts by a mechanism independent of RARs or as an RAR-g agonist (Cliord et al., 1999; Dmitrovsky, 1997) , and observed that 4-HPR had no eect on COX-2 expression in TE-8S20 cells (Figure 5b ). These experiments, together with data shown above and previously, demonstrate that the eect of RA on COX-2 expression is mediated by RAR and suggest that inhibition of COX-2 expression is dependent on RAR-b expression.
Discussion
The association between vitamin A levels and cancer development suggests that retinoid-dependent signaling pathways may play an important role in regulating cell growth and dierentiation and suppressing carcinogenesis (De Luca, 1991; Gudas, 1992; Chambon, 1996; Sporn et al., 1994; Pfahl and Chytil, 1996; . The pathways could be abrogated by changes in the expression of speci®c nuclear retinoid receptors. Indeed, a major ®nding in recent studies is that RAR-b expression is frequently decreased in various premalignant lesions and the subsequent cancers (Gebert et al., 1991; Hu et al., 1991; Geradts et al., 1993; Swisshelm et al., 1994; Lotan et al., 1995; Qiu et al., 1999; Xu et al., 1997a Xu et al., ,b, 1999 . Previous studies have demonstrated that lung carcinoma cells expressing transfected RAR-b exhibit decreased tumorigenicity in nude mice (Houle et al., 1993) and that transgenic mice expressing antisense RAR-b 2 develop lung cancer (Berard et al., 1996) . Another study has showed that knocking out RAR-b 2 by homologous recombination in F9 cells results in the loss of RA-associated growth arrest and altered cell morphology, and dierentiation potential (Faria et al., 1999) . However, it remains largely unknown how RAR-b suppresses carcinogenesis and how its eect is mediated, although several reports have demonstrated that RAR-b plays a role in the regulation of growth and apoptosis (Berard et al., 1996; Liu et al., 1996; Seewaldt et al., 1995; . In particular, little is known about RAR-b-regulated genes (Faria et al., 1999) . In this study, we demonstrated that COX-2 may be one of the RAR-b target genes because it was downregulated in RAR-b-transfected esophageal cancer cells, whereas it is upregulated by inhibition of RAR-b expression in RAR-b-positive cells. Moreover, bile acidinduced expression of COX-2 mRNA and protein as well as PGE 2 production in both RAR-b and vector-only transfectants were blocked by RA only in the RAR-bpositive cells, suggesting that RAR-b mediates the eect of RA. Recently, we have demonstrated that induction of apoptosis by NS398 in esophageal cancer cells is associated with COX-2 expression. Speci®cally, TE-8 and TE-13 cells, which express COX-2, were sensitive to NS398 and underwent apoptosis after 2 days of treatment with NS398, whereas TE-1 cells, which do not express COX-2 were much less sensitive to NS398. This association was further con®rmed by the addition of PGE 2 , which was able to block both NS398-induced cytochrome c release from mitochondria and apoptosis in esophageal cancer cells (Li et al., 2001) , and by a recent publication, which studied the eect of low dose (up to 10 mM) of NS398 in three esophageal adenocarcinoma cell lines (Souza et al., 2000) . Although the exact role of PGE 2 in human carcinogenesis remains unclear, PGE 2 is usually overproduced in dierent cancer tissues and cell lines and may promote cell growth and carcinogenesis (see review in Marnett (1992) and Taketo (1998a,b) ). As stated in Introduction, dierent tumor promoters and growth factors can signi®cantly increase COX-2 expression, which in turn promotes carcinogenesis. NSAIDs, however, can inhibit COX-2 enzymatic activity and prevent cancer development in patients.
In this study, we found that COX-2 expression was reduced in RAR-b-transfected TE-8 subclones as compared to that in the parental and vector onlytransfected cells. Furthermore, RA inhibited COX-2 expression and its induction by bile acid only in RARb-transfected cells, but not in the parental or vectoronly transfectants. These observations demonstrated that RAR-b plays an important role in mediating RA eect on COX-2 expression. The ®ndings that the RAR antagonist AGN193109 could block RA action and that 4-HPR had no eect on COX-2 expression further support the notion that inhibition of COX-2 expression is dependent on RAR-b expression. In addition, our unpublished data using samples from a clinical prevention trial of 13-cis RA-treated patients with oral premalignant lesion showed that baseline tissue sections have lost RAR-b expression and increased COX-2 expression. However, RAR-b was re-expressed and COX-2 is decreased after a 3-month treatment with 13-cis-RA, which supports our present ®ndings.
Although our study supports the important role of RAR-b in COX-2 reduction by RA, the involvement of other retinoid receptors could not be excluded. However, it is unlikely that RAR-a and RAR-g are involved in mediating the growth inhibitory eect of RA in TE-8 cells since both the receptors are expressed in these cells, which are resistant to RA. Similarly, RAR-a and RAR-g may not play a role in regulating COX-2 expression. A study of RAR-knockout F9 cells indicated that the RARs regulate the expression of dierent genes and suggested that each RAR has a dierent function (Faria et al., 1999) and controls dierent downstream genes, which in turn mediate a large number of physiological and pharmacological eects of RA on cell growth and dierentiation and carcinogenesis. In the present study, we report that the COX-2 protein may be one of these genes that are controlled by RAR-b. Dierential display PCR and gene array techniques have been also used to further explore RAR-b-regulated genes in several dierent laboratories, including our own. After completion of these studies, we will be able to know expression pro®le of RAR-b-controlled genes.
Experiments of nuclear run-o and luciferase assays showed that the inhibition of COX-2 induction by bile acid occurred at the transcriptional level. RAR-b may directly bind to the COX-2 promoter sequence to regulate its transcriptional activity. Although the promoter does not contain a consensus DR5 retinoic acid response element, a putative DR1 retinoic acid response element site and some half sites were found (Kosaka et al., 1994) . Whether RAR-b can bind to these sequences remains to be determined. Alternatively, RARs were found to be potent inhibitors of AP-1 activity generated either by c-Jun homodimers or cJun/c-Fos heterodimers (Yang-Yen et al., 1991) . More recently, Lin et al. (2000) showed that RAR-b can inhibit AP-1 activity. Therefore, RAR-b may indirectly regulate COX-2 promoter activity through its inter- ; our unpublished data). NSAIDs can inhibit COX-2 enzymatic activity and block AP-1 activation (Dong et al., 1997; Tegeder et al., 2001) . Thus, combination of RA and NSAIDs may greatly enhance the individual drug activity for the prevention of esophageal cancer.
Materials and methods
Cell culture and treatment
Esophageal squamous cell cancer cell lines TE-3 and TE-8 and their transfectants were plated in tissue-culture dishes and grown in Dulbecco's modi®ed Eagle's medium (DMEM) with 10% fetal bovine serum (FBS) at 378C in a humidi®ed atmosphere of 95% air and 5% CO 2 . To examine the eects of RA and chenodeoxycholate (CD) (Sigma Chemicals Co., St. Louis, MO, USA), the cells were plated in DMEM and incubated for 24 h, and then the medium was replaced with either control medium containing 0.01% dimethylsulfoxide (DMSO) or with medium containing 1 mM RA or 400 mM CD. Both RA and CD were dissolved in DMSO and diluted into the medium before each experiment. To examine the inhibitory eect of RA on the induction of COX-2 expression by CD, cell lines were treated with 1 mM RA for 8 h and then treated with 400 mM CD for 12 h. To examine the eects of 4-HPR and the RAR antagonist AGN193109 on COX-2 expression in TE-8 cells, we dissolved both drugs in DMSO and used 2.5 or 5 mM 4-HPR and 10 mM AGN193109 to treat the TE-8 cells as we did with RA or CD.
Stable transfection
RAR-b cDNA was cloned into the expression vector pRC/ CMV (Invitrogen, San Diego, CA, USA) in the sense and antisense orientations as described previously (Liu et al., 1996) . The RAR-b expression vector was stably transfected into TE-8 cells (to make TE-8S20 and TE-8S22) and the antisense construct into TE-3 cells (to make TE-3A3 and TE-3A5) with Lipofectin and screened with 400 mg/ml of G418 (both from Gibco BRL, Grand Island, NY, USA). TE-3, and TE-8 stably transfected with the control vector were named TE-3V1, and TE-8V1, respectively.
Cell viability assay
The cells were plated in regular medium for 24 h, and the medium was then replaced with either control medium (containing 0.01% DMSO) or medium with 1 mM RA or 10 mM PGE 2 (Cayman). The medium was completely replaced with fresh medium every 72 h. At the end of the experiment, the cells were ®xed with 10% trichloroacetic acid, and stained with 0.4% sulforhodamine B in 1% acetic acid, and then the optical densities were read with an automated spectrophotometric plate reader at a single wavelength of 490 nm. Cell viability was tested by exclusion of Trypan blue (0.1%), and the per cent of control of viable cells was determined by the equation: 1-(ODt/ODc)6100 where ODt and ODc are optical densities of treated and control cultures, respectively.
RNA purification and Northern blotting
RNA was extracted from monolayer cultures by using TriReagent (Molecular Research Center, Cincinnati, OH, USA) as described before . The plasmid pCDNA1/ COX2, which contains the human COX-2 cDNA (Hla and Neilson, 1992) , was cut with EcoRI plus XbaI, and a 1.95-kb fragment was isolated for use as probe for Northern blotting.
Nuclear protein extraction and Western blotting
Extraction of nuclear proteins was described in Song and Xu (2001) . Brie¯y, nearly con¯uent monolayer cell cultures were washed with phosphate-buered saline (PBS); harvested by scraping into 1 ml of PBS; and centrifuged, and then the pellet was suspended in 200 ml of lysis buer A containing 10 mM HEPES, pH 7.9, 10 mM KCl; 0.5 mM EDTA; 1.5 mM MgCl 2 ; 0.25% Nonidet P-40; 1 mM dithiothreitol (DTT); and 0.1 mM phenylmethylsulfonyl¯uoride (PMSF). The crude nuclear pellet was recovered and resuspended in 100 ml of extraction buer C containing 20 mM HEPES, pH 7.9; 420 mM NaCl; 0.1 mM EDTA; 1.5 mM MgCl 2 ; 25% glycerol; 1 mM DTT; and 0.5 mM PMSF and rocked for 60 min at 48C. After centrifugation at 14 000 r.p.m. for 30 min, the supernatant was removed and saved at 7208C. The protein concentration was then measured with a Bio-Rad Protein Assay kit II (Bio-Rad Laboratories, Hercules, CA, USA). Samples containing 50 mg of nuclear protein were separated in 10% SDS ± PAGE gels and then transferred electrophoretically to a Hybond-C nitrocellulose membrane (AmershamPharmacia). The membrane was subsequently stained in 0.5% Ponceau S with 1% acetic acid to con®rm equal loading and transfer eciency. For Western blotting, the membranes were incubated overnight in a blocking solution containing 5% bovine skim milk and 0.1% Tween 20 and then incubated for 2 h with anti-RAR-b antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at room temperature. The membranes were subsequently incubated for 1 h with horse anti-mouse secondary antibody (Amersham-Pharmacia). Then, the membranes were incubated with enhanced chemiluminescence solution (Amersham-Pharmacia) for 1 ± 2 min and exposed to X-ray ®lm.
Cellular protein extraction and Western blotting
Cellular proteins were isolated in lysis buer containing 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 10 mg/ml PMSF, 30 mg/ml aprotinin, and 50 mM Tris-HCl, pH 8.0. The protein concentration in the samples was measured with a Bio-Rad Protein Assay Kit II. Samples containing 30 mg of protein were subjected to electrophoresis and transferred to Hybond-C nitrocellulose membranes as above. The membranes were incubated for 3 h with anti-COX-1 (Cayman Chemicals, Ann Arbor, MI, USA), anti-COX-2 (Transduction Laboratories, Lexington, KY, USA), and antib-actin antibodies (Sigma) and processed as stated above.
Enzyme-linked immunosorbant assay (ELISA) of PGE 2 production Cells (2610 4 /well) were plated in 24-well dishes and grown to 80% con¯uence in DMEM containing 10% FBS. The medium was then replaced with DMEM containing 1% FBS and 0.01% DMSO, 400 mM CD, or 400 mM CD plus 1 mM RA for 12 h. The conditioned medium was then collected, and PGE 2 was measured with a commercial kit (Cayman) according to the manufacturer's protocol.
Nuclear run-off assay
This assay was performed as described previously (Carey and Smale, 2000) . Nuclei from TE-8 cells were isolated by using NP-40 lysis buer (10 mM Tris-HCl, pH 7.4; 10 mM NaCl; 3 mM MgCl 2 ; and 0.5% NP-40) and stored at 7808C in storage buer (50 mM Tris-HCl, pH 8.3; 5 mM MgCl 2 ; 0.1 mM EDTA; and 40% glycerol) before use. Nuclei from about 5610 7 cells in 100 ml of storage buer were used for the transcription assay after thawing and incubation in 100 ml of 26 reaction buer (10 mM Tris-HCl, pH 8.0; 5 mM MgCl 2 ; 0.3 M KCl; 0.2 mM EDTA; 1 mM DDT; and 4 mM each ATP, CTP and GTP) and 100 mCi of a-32 P-UTP at 308C for 30 min. To remove template DNA after transcription, 10 ml of RNAse-free DNAse I and 10 ml of 1 M CaCl 2 were added to the mixture and incubated at 268C for 30 min. To digest protein in the mixture, 25 ml of 106 SET (5% SDS; 50 mM EDTA; and 100 mM Tris-HCl), 2 ml of 100 mg/ ml proteinase K, and 5 ml of tRNA (Roche Molecular Biochemicals, Indianapolis, IN, USA) were added to the mixture, which was then incubated at 378C for 30 min. The labeled nascent RNA transcripts were isolated with 0.75 ml of Tri-Reagent (Molecular Research Center) plus 0.2 ml of chloroform and precipitated with isopropanol. Then, the pellet was washed with 70% ice-cold ethanol and dissolved in 100 ml of 0.2% SDS. To detect newly synthesized RNA, 1 mg of COX-2 cDNA and 1 mg of GAPDH cDNA (as a control) were immobilized separately onto nitrocellulose, prehybridized at 658C for 2 h in hybridization buer (AmershamPharmacia), and then hybridized at 658C for 24 h with 106 c.p.m./ml labeled nascent RNA transcripts from each experiment. The membranes were then washed twice with 26 SSC at 658C for 20 min and exposed to X-ray ®lm for 24 h.
Transient transfection and luciferase assay
TE-8 cells were seeded at a concentration of 1.5610 5 cell per well in six-well plates. After overnight culture, the cells in each well were transfected with 2 mg of DNA (1.5 mg of COX-2 promoter-Luciferase reporter plasmid, 0.1 mg of pCH110 (Amersham-Pharmacia), (b-galactosidase expression vector used as an internal control for transfection eciency), and/or 0.4 mg of pRC/CMV-RAR-b expression vector (same one used for stable transfection)) by using 6 ml of LipofectAMINE (Life Technologies, Inc.) by following the manufacturer's protocol. The COX-2 promoter (7375 to +59) was ampli®ed from human genomic DNA by using the primers 5'-GAGTCTCTTATTTATTTTT-3' (sense) and 5'-GCTGCTGAGGAGTTCCTGGACGTGC-3' (antisense). HindIII linkers (New England Biolabs, Inc., Beverly, MA, USA) were added before cloning into the HindIII site of PGL2 basic vector (Promega). Sequencing analysis showed that our COX-2 promoter was the reported one (Kosaka et al., 1994) . After a 6-h exposure to the transfection mixture, the cells were incubated in medium containing 10% FBS and 400 mM CD, 1 mM RA, or DMSO for 12 h and then harvested. Luciferase activity was measured by using the Promega luciferase assay system according to the manufacturer's protocol and detected by using Lumat LB9507 (EG&G Berthold, Bad Wilbad, Germany) in relative light units normalized to the b-galactosidase activity to account for dierences in transfection eciency. All experiments are performed in triplicates, and repeated at least twice to prove their reproducibility.
